Gary Chicchi

Gary Chicchi

UNVERIFIED PROFILE

Are you Gary Chicchi?   Register this Author

Register author
Gary Chicchi

Gary Chicchi

Publications by authors named "Gary Chicchi"

Are you Gary Chicchi?   Register this Author

40Publications

1117Reads

7Profile Views

A novel series of indazole-/indole-based glucagon receptor antagonists.

Bioorg Med Chem Lett 2015 Oct 8;25(19):4143-7. Epub 2015 Aug 8.

Early Development and Discovery Science, and Preclinical Development, Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2015.08.015DOI Listing
October 2015

Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.

ACS Med Chem Lett 2015 Aug 10;6(8):936-41. Epub 2015 Jul 10.

Departments of Medicinal Chemistry, Diabetes Biology, Pharmacology, Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Basic Pharmaceutical Sciences, Chemical Modeling and Informatics, and Process Research, Merck Research Laboratories , Rahway, New Jersey 07065, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.5b00207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538435PMC
August 2015

Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.

Am J Physiol Endocrinol Metab 2012 Jul 22;303(2):E265-71. Epub 2012 May 22.

In Vivo Pharmacology, Merck Sharp & Dohme Corporation, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpendo.00142.2012DOI Listing
July 2012

Design of potent and selective GPR119 agonists for type II diabetes.

Bioorg Med Chem Lett 2011 May 22;21(9):2665-9. Epub 2010 Dec 22.

Department of Medicinal Chemistry, Merck & Co., Inc., PO Box 2000 Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.12.086DOI Listing
May 2011

Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.

Bioorg Med Chem Lett 2010 Oct 19;20(19):5925-32. Epub 2010 Jul 19.

Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.07.058DOI Listing
October 2010

Tetrahydroindolizinone NK1 antagonists.

Bioorg Med Chem Lett 2010 Apr 1;20(7):2354-8. Epub 2010 Feb 1.

Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.01.120DOI Listing
April 2010

Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists.

Bioorg Med Chem 2008 Mar 5;16(5):2156-70. Epub 2007 Dec 5.

Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, 126 E. Lincoln Avenue, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2007.11.081DOI Listing
March 2008

Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.

Bioorg Med Chem Lett 2007 Oct 16;17(19):5310-5. Epub 2007 Aug 16.

Department of Medicinal Chemistry, Merck Research Laboratories, PO 2000, Rahway, NJ 07065-0900, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2007.08.028DOI Listing
October 2007

N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.

Bioorg Med Chem Lett 2006 Nov 6;16(22):5752-6. Epub 2006 Sep 6.

Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2006.08.085DOI Listing
November 2006

N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.

Bioorg Med Chem Lett 2006 Nov 6;16(22):5748-51. Epub 2006 Sep 6.

Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2006.08.086DOI Listing
November 2006

Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.

Bioorg Med Chem Lett 2006 Sep 7;16(17):4497-503. Epub 2006 Jul 7.

Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2006.06.035DOI Listing
September 2006

NK1 antagonists based on seven membered lactam scaffolds.

Bioorg Med Chem Lett 2006 Jun 29;16(11):2929-32. Epub 2006 Mar 29.

Department of Medicinal Chemistry, Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2006.02.080DOI Listing
June 2006

1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists.

Bioorg Med Chem Lett 2006 Apr 18;16(7):2008-12. Epub 2006 Jan 18.

Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Harlow, Essex CM20 2QR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.12.069DOI Listing
April 2006

Novel lactam NK1 antagonists with anti-emetic activity.

Bioorg Med Chem Lett 2006 Mar 27;16(5):1197-201. Epub 2005 Dec 27.

Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.11.111DOI Listing
March 2006

Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonists.

Bioorg Med Chem Lett 2006 Feb 22;16(4):811-4. Epub 2005 Nov 22.

Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Harlow, Essex CM20 2QR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.11.026DOI Listing
February 2006

Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets.

Drug Metab Dispos 2003 Jun;31(6):785-91

Department of Drug Metabolism, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.31.6.785DOI Listing
June 2003

Spirocyclic NK(1) antagonists II: [4.5]-spiroethers.

Bioorg Med Chem Lett 2002 Oct;12(19):2719-22

Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(02)00509-7DOI Listing
October 2002

Identification, localization and receptor characterization of novel mammalian substance P-like peptides.

Gene 2002 Aug;296(1-2):205-12

Department of Immunology/Rheumatology, Merck Research Laboratories, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0378-1119(02)00861-2DOI Listing
August 2002

4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists I.

Bioorg Med Chem Lett 2002 Jul;12(13):1755-8

Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(02)00249-4DOI Listing
July 2002

4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists II.

Bioorg Med Chem Lett 2002 Jul;12(13):1759-62

Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(02)00250-0DOI Listing
July 2002